In English
Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins.
Int J Hematol 81:100-105, 2005
Oritani K, Kanakura Y. IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression.
J Cell Mol Med 9:244-254, 2005
Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, Fujioka T, Masuda T, Kawase I, Ogawa H. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism.
Clin Lab Haematol 27:139-141, 2005
Kashiwagi H, Shiraga M, Kato H, Honda S, Sako M, Kurata Y, Kanakura Y, Tomiyama Y. Expression and subcellular localization of WAVE isoforms in the megakaryocyte/platelet lineage.
J Thromb Haemost 3:361-368, 2005
Kashiwagi H, Shiraga M, Kato H, Kamae T, Yamamoto N, Tadokoro S, Kurata Y, Tomiyama Y, Kanakura Y. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A.
Blood 106:913-921, 2005
Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, Kurata Y, Tomiyama Y, Kanakura Y. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon.
J Thromb Haemost 3:2315-2323, 2005
Shirogane T, Jin J, Ang XL, Harper JW. SCF(beta)-TRCP controls Clock-dependent transcription via Casein kinase 1-dependent degradation of the mammalian Period-1(Per1) protein.
J Biol Chem 280:26863-26872, 2005
Ishida N, Oritani K, Shiraga M, Yoshida H, Kawamoto S, Ujiie H, Masaie H, Ichii M, Tomiyama Y, Kanakura Y. Differential effects of a novel IFN-zeta/limitin and IFN-alpha on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes.
Exp Hematol 33:495-503, 2005
Tanaka H, Matsumura I, Kanakura Y. Cell cycle regulation in hematopoietic stem/progenitor cells.
J Biol Sci 5:50-60, 2005
Tanaka H, Matsumura I, Yamashiro K, Kanakura Y. Cell cycle regulation in hematopoietic stem/progenitor cells.
Trends in Cell & Molecular Biology 1:51-60, 2005
Ezoe S, Matsumura I, Gale K, Satoh Y, Ishikawa J, Mizuki M, Takahashi S, Minegishi N, Nakajima K, Yamamoto M, Enver T, Kanakura Y. GATA transcription factors inhibit cytokine-dependent growth and survival of a hematopoietic cell line through the inhibition of STAT3 activity.
J Biol Chem 280:13163-13170, 2005
Kato H, Honda S, Yoshida H, Kashiwagi H, Shiraga M, Honma N, Kurata Y, Tomiyama Y. SHPS-1 negatively regulates integrin αIIbβ3 function through CD47 without disturbing FAK phosphorylation.
J Thromb Haemost 3:763-774, 2005
Ishiko J, Mizuki M, Matsumura I, Shibayama H, Sugahara H, Scholz G, Serve H, Kanakura Y. Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.
Oncogene 24:8144-8153, 2005
Ishiko E, Matsumura I, Ezoe S, Gale K, Ishiko J, Satoh Y, Tanaka H, Shibayama H, Mizuki M, Era T, Enver T, Kanakura Y. Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1.
J Biol Chem 280:4929-4939, 2005
Sakane-Ishikawa E, Nakatsuka S, Tomita Y, Fujita S, Nakamichi I, Takakuwa T, Sugiyama H, Fukuhara S, Hino M, Kanamaru A, Soma T, Tsukaguchi M, Igarashi K, Kanamaru Y, Aozasa K. Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group.
J Clin Oncol 23:8012-8017, 2005
Kabutomori O, Kanakura Y, Iwatani Y. Inflammation markers and liver dysfunction.
Ann Hematol 84:136, 2005
Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Clin Chem 51:545-552, 2005
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Komada F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.
Blood 106:2627-2632, 2005
Koma Y, Ito A, Watabe K, Hirata T, Mizuki M, Yokozaki H, Kitamura T, Kanakura Y, Kitamura Y. Distinct role for c-kit receptor tyrosine kinase and SgIGSF adhesion molecule in attachment of mast cells to fibroblasts.
Lab Invest 85:426-35, 2005
Aoki T, Tomiyama Y, Honda S, Mihara K, Yamanaka T, Okubo M, Moriguchi A, Mutoh S. Association of the antagonism of von Willebrand factor but not fibrinogen by platelet alphabeta antagonists with prolongation of bleeding time.
J Thromb Haemost 3:2307-2314, 2005
Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M, Uozumi N, Ihara S, Lee S-H, Ikeda Y, Yamaguchi Y, Aze Y, Tomiyama Y, Fujii J, Suzuki K, Kondo A, Shapiro S, Lopez-Otin S, Kuwaki T, Okabe M, Honke K, Taniguchi N. Dysregulation of TGF-b1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice.
Proc Natl Acad Sci USA 102:15791-15796, 2005
Ishii T, Onda H, Tanigawa A, Ohshima S, Fujiwara H, Mima T, Katada Y, Deguchi H, Suemura M, Miyake T, Miyatake K, Kawase I, Shao H, Tomiyama Y, Saeki Y, Nojima H. Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients.
DNA Res 12:429-439, 2005
Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K, Shimoda K, Minoguchi M, Yoshimura A, Matsuda T. Physical and functional interactions between STAP-2/BKS and STAT5.
J Biol Chem 280:8188-8196, 2005
Kawakami M, Nakata J, Ohguro N, Yoshihara S, Inoue T, Tatekawa T, Ikegame K, Oka Y, Kawase I, Ogawa H. A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis.
Eur J Haematol 75:352-354, 2005
Pelayo R, Welner R, Perry SS, Huang J, Baba Y, Yokota T, Kincade PW. Lymphoid progenitors and primary routes to becoming cells of the immune system.
Curr Opin Immunol 17:100-107, 2005
Igarashi H, Medina KL, Yokota T, Rossi MID, Sakaguchi N, Comp PC, Kincade PW. Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoids.
Int Immunol 17:501-511, 2005
Kouro T, Yokota T, Welner R, Kincade PW. Isolation of prolymphocytes from bone marrow and fetal liver.
Current Protocols in Immunology 22F.1.1-22F.1.9, 2005
Kouro T, Yokota T, Welner R, Kincade PW. In vitro differentiation and measurement of B cell progenitor activity in culture.
Current Protocols in Immunology 22F.2.1-22F.2.12, 2005
Kouro T, Yokota T, Welner R, Kincade PW. Measurement of natural killer cell progenitor activity in culture.
Current Protocols in Immunology 22F.3.1-22F.3.4, 2005
Yao L, Yokota T, Xia L, Kincade PW, McEver RP. Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells.
Blood 106:4093-4101, 2005
In Japanese
金倉 譲. 悪性リンパ腫up-to-date "混沌よりあらたなエビデンスを求めて はじめに. 医学のあゆみ 212:291, 2005
金倉 譲. CLLの新たな予後推定因子ZAP-70. Annual Review 血液 2005(高久文磨,溝口秀昭,坂田洋一,金倉 譲, 小島勢二編),中外医学社,東京, 2005, pp190-199
金倉 譲. 臨床血液学 "進歩の軌跡と今後の展望 ". 綜合臨牀 54:1723-1724, 2005
金倉 譲, 水木満佐央. 悪性リンパ腫に対する化学療法. インフォームド・コンセント-その理論と書式実例(前田正一編), 医学書院, 東京, 2005, pp152-158
松村 到. Hyper eosinophic syndrome (HES)の病態と新たな治療:Imatinib療法と抗IL-5抗体療法. Annual Review 血液2005(高久文磨,溝口秀昭,坂田洋一,金倉 譲, 小島勢二編),中外医学社,東京, 2005, pp151-162
松村 到,金倉 譲. ファルネシル化阻害剤. 血液・腫瘍科 50:42-52, 2005
松村 到,金倉 譲. ファルネシル化阻害剤. Mebio 22:74-80, 2005
松村 到. 新たな分子標的療法剤. 総合臨床 54:1799-1804, 2005
松村 到. JunB欠損マウスに発症するCML様病態における白血病幹細胞の起源. 分子細胞治療 4:98-99, 2005
松村 到,金倉 譲. 造血細胞における転写因子:総論. 医学のあゆみ 血液疾患 Ver.3(坂田洋一,小澤敬也編),医歯薬出版株式会社,東京, 2005, pp48-51
松村 到,金倉 譲. ファルネシルトランスフェラーゼ阻害剤. 臨床腫瘍内科学入門(金倉 譲編),永井書店,大阪,2005, pp60-63
松村 到. プロテアソーム阻害剤. 臨床腫瘍内科学入門(金倉 譲編),永井書店,大阪, 2005, pp64-66
松村 到,金倉 譲. Farnesyl transferase阻害剤. 分子標的治療薬(元吉和夫,大野竜三編),メデイカルレビュー社,東京, 2005, pp133-142
松村 到,金倉 譲. 細胞周期の制御機構. 三輪血液病学(浅野茂隆,池田康夫,内山 卓監修), 文光堂,東京, 2005, pp99-103
松村 到,金倉 譲. 好酸球,好塩基球および肥満細胞の異常. 三輪血液病学(浅野茂隆,池田康夫,内山 卓監修), 文光堂,東京, 2005, pp1308-1320
松村 到,金倉 譲. 急性白血病の分類(FAB分類とWHO分類) . 三輪血液病学(浅野茂隆,池田康夫,内山 卓監修), 文光堂,東京, 2005, pp1374-1408
松村 到,金倉 譲. 白血病. 内科 96:1028-1036, 2005
松村 到,金倉 譲. サイトカインmimeticsの臨床応用. 実験医学増刊 Vol.23 No.20(宮島 篤, 北村俊雄編),羊土社,東京, 2005, pp182-187